2 Best Healthcare sector Stocks: Raptor Pharmaceutical Corp. (RPTP), Unilife Corp (UNIS)


Raptor Pharmaceutical Corp. (NASDAQ:RPTP)

Stock’s Trading Stats:

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) declined -6.62% yesterday and closed at $5.08. The company’s market capitalization is at $404.38 Million with an average trading volume of 1.26 Million. The total number of Outstanding Shares Held by the company are 85.24 Million.

Recent Press Release:

Raptor Pharmaceutical Corp. (RPTP) on April 11, 2016 declared its first commercial sale of QUINSAIR™ (levofloxacin inhalation solution) in Germany and Denmark. QUINSAIR is approved in the European Union (EU) and Canada for the administration of chronic pulmonary infections because of Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF). It is the first fluoroquinolone to be approved as an inhaled therapy for a pulmonary disease. The treatment is administered twice-daily, stored at room temperature and has a short administration time. Launches in additional EU countries and Canada are anticipated for QUINSAIR in 2016.

QUINSAIR is a proprietary inhaled formulation of levofloxacin, a fluoroquinolone antibiotic, which is approved in the European Union and Canada for the administration of chronic pulmonary infections because of Pseudomonas aeruginosa in adult patients with CF. Administration of QUINSAIR with the high efficiency Zirela® Nebulizer System (PARI Pharma GmbH) allows for the delivery of high concentrations of active drug directly to the site of infection in about five minutes. QUINSAIR is contraindicated in patients with hypersensitivity to levofloxacin, a history of tendon disorders related to fluoroquinolones, or epilepsy and also patients who may be pregnant or breast feeding. QUINSAIR’s safety was evaluated in two double-blind, placebo-controlled studies and an active comparator study in which the most frequently stated adverse reactions were cough/productive cough, dysgeusia and fatigue/asthenia.

Unilife Corp (NASDAQ:UNIS)

Stock’s Trading Stats:

Unilife Corp (NASDAQ:UNIS) closed at $0.61 yesterday by showing a decrease of -6.20%. The total number of outstanding shares held by the company are 169.44 Million with the total market capitalization of $96.92 Million. The number of shares traded on the last trading session are 923,459.

Recent Press Release:

Unilife Corp (UNIS) on March 14, 2016 declared the realignment of its business units and leadership team to efficiently focus operations on the revenue-generating programs of key planned customers.

Following the successful completion of the review of planned alternatives by the Unilife Board of Directors, the Company has streamlined its operations into two program-focused business units:

  • Wearable and Auto Injectors: Executing to customer programs for wearable injectors, reusable auto injectors and instant patch pumps for insulin.
  • Prefilled Syringes: Executing to customer programs for prefilled syringes; in addition to ocular, reconstitution and novel delivery systems.

As Interim CEO, John Ryan brings more than two decades of experience in business, law and government to the role.  Joining Unilife in 2014, Mr. Ryan was formerly a Partner at Duane Morris LLP, a Senior Vice President and Deputy General Counsel of Aramark Corporation and an Assistant District Attorney at the Manhattan District Attorney’s Office.